Methotrexate for Injection USP

DECEMBER 01, 2005

Bedford Laboratories (Bedford, Ohio), a division of Ben Venue Laboratories Inc, recently added Methotrexate for Injection USP, 1 g, to its line of oncology products. Methotrexate for Injection USP is indicated for the treatment of certain neoplastic diseases, severe psoriasis, and adult rheumatoid arthritis. The product is supplied in 4 singledose, preservative-free liquid presentations, containing 25 mg/mL of methotrexate sodium?50 mg in 2 mL, 100 mg in 4 mL, 200 mg in 8 mL, 250 mg in 10 mL?and in a 1- g single-dose, preservative-free lyophilized powder. For more information, visit www.bedfordlabs.com, or call 800-521-5169.



SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.